ALIF_B: Strong margin gains, robust cash flow, and new acquisition drive positive outlook

About this update from Addlife Ab Class B

EBITDA margins improved significantly in both lab tech and med tech, with strong cash flow reducing leverage to 2.8x EBITDA. Revenue growth was robust in most geographies, and the acquisition of Edge Medical supports a more active M&A agenda.Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Addlife Ab Class B